Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Another UK Biotech Snapped Up As Neurocrine Buys Diurnal

US Firm Paying Just £48m

Aug 30 2022

• By Kevin Grogan

A pair of feet standing on a tarmac road with yellow arrow print pointing in three different directions for the concept of making decision at the crossroad. — Diurnal plumps for the takeover route • Source: Archive

Related Content

Diurnal Adrenal Franchise Takes Shape With Alkindi Launch

May 22 2018

Diurnal Renames Orphan Drug As Efmody, Expecting EU-Wide Approval

Mar 26 2021

Eagle Lands On COVID-Hit Acacia

Mar 28 2022

Major Milestone For Diurnal As FDA Approves Alkindi

Sep 30 2020

Gilead Grabs MiroBio's Checkpoint Agonists For $405m

Aug 04 2022

Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

Dec 08 2021

Related Companies

Diurnal Group PLC

Neurocrine Biosciences, Inc.

MiroBio

Gilead Sciences, Inc.

Eagle Pharmaceuticals, Inc.

Acacia Pharma Group plc

Additional Topics

M & A Business Strategies Rare Diseases Commercial Companies Deals BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window